Anzalone Christopher Richard bought ARWR
December 12, 2025 · Form 4 insider transaction
Anzalone Christopher Richard bought 180,000 shares of Arrowhead Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
180,000
Price
$0.00
Total value
N/A
InsiderAnzalone Christopher Richard
Role—
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateDecember 12, 2025
Filing dateDecember 16, 2025
Shares owned after4,101,255
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Represents shares underlying restricted stock units with a grant date December 12, 2025, which will vest in four equal annual installments.; Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.